Compare Adaptive Biotechnologies Corp (ADPT) vs Axogen Inc (AXGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Axogen Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while Axogen Inc trades at $43.2 (market cap $2.37B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Axogen Inc is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | AXGN | |
|---|---|---|
Market Cap | $3.33B | $2.37B |
Sector | Health | Technology |
52-Week High | $22.37 | $46.19 |
52-Week Low | $10.24 | $11.28 |
Enterprise Value | $3.19B | $2.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AXGN trades at $45.97, up 0.17% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 earnings of $0.07 per share, missing estimates, yet maintains a strong gross margin of 75.01%. Recent news highlights a bullish rebound and raised 2026 guidance, with 84% of analysts rating it a Buy. Support is at $44, with resistance at $47.
Outlook is cautiously optimistic due to strong analyst support and recent institutional interest, but risks include consecutive earnings misses and negative net income margins. The consensus price target of $47.60 suggests modest upside, though execution on guidance and reimbursement wins are critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →
